Recent Updates
Recently added Catalysts

Perindopril-indapamide

Phase 3

Diabetes Mellitus, Type 2 | Small molecule | Metabolic |Tango Therapeutics, Inc.|Last Updated: Apr 11, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment11,140
FDA Designations
No designations recorded
Clinical trial landscape

Perindopril-indapamide · 1 trial · 1 indication

Phase 3 1
NCT00145925Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 DiabetesDiabetes Mellitus, Type 2
COMPLETED11,140 Analytics
PHASE3COMPLETED
Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
NCT0014592511,140
Unlock trial analytics
Study Endpoints
Primary Endpoints
Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause
July 2001 - December 2007
Composite of new or substantially worsening nephropathy or microvascular eye disease.
July 2001 - December 2007
Secondary Endpoints
Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.
July 2001 - December 2007
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelFACTORIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Blood pressurePLACEBO_COMPARATORPerindopril indapamide vs placebo
Glucose controlOTHERStandard versus intensive glucose control
Interventions
NameTypeDescription
Perindopril-indapamideDRUG -
Gliclazide MR-based glucose loweringDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range55 Years to 110 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: 1. A diagnosis of type 2 diabetes mellitus first made at age 30 years or older 2. Age 55 years or older at entry 3. Ability to provide informed consent 4. A substantially elevated risk of cardiovascular disease, indicated by: * A history of major macrovascular disease define...

Countries:AustraliaCanadaChinaNetherlandsUnited Kingdom
Unlock Eligibility Criteria